Last Friday after the bell everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), filed a new Form S-3 revealing (as predicted) the supposedly “above market non-dilutive” deals with penny stock financier John M. Fife were actually highly dilutive forward-priced time bombs. Read about those deals here and here, and background about John here here and here.

We will explore that filing in more detail very soon. For the moment, however, we should not lose momentum in uncovering all of the dirty secrets The NaDDir* and his klown krew of kreme de la kreme managers don’t want investors to ever learn about. You know, the details in the lawsuit Alpha Venture Capital Partners LP v Cytodyn (CYDY), Pourhassan, et al. (Delaware Chancery Court 2020-0307-PAF) dated April 24, 2020. The one the company doesn’t properly disclose to investors, making it highly unlikely any of them would learn of its existence. Notice anything missing in this listing of legal proceedings involving Cytodyn?

If you were thinking the April 24th case by the former directors has been omitted, you are correct. Glaringly omitted. Unfortunately for Cytodyn, the Streisand Effect is real. As a holiday gift to you, dear readers, the lawsuit, in full unredacted glory, is available right here.

OK, did you read it? All of it? No? Go back, click on the link, and read it. OK, Good. With that housekeeping out of the way, let’s move on to some Sunday fun.

How many readers recall the curiously short tenure of Cytodyn board member Michael A. Klump. Back in the summer of 2018, the company made much of the fact that they managed to get a fairly well known real estate and restaurant investor to take a seat on their board. One might recall the press release from August 13, 2018 which trumpeted his arrival:

His departure on January 15, 2020 must have come as quite a surprise to all involved, especially as it was not revealed until the 21st of January, in a throwaway paragraph in a press release that day about something else entirely. Here is the company’s explanation of Klump’s departure:

The corresponding 8K filed by Cytodyn with the SEC was more succinct, and mentioned nothing about Klump becoming an advisor:

Always remember, when a press release and an 8k don’t have full concordance on every single point, the press release is a lie. Plain and simple (and in this case, because nothing with Cytodyn is simple, not even their deceit, it seems the 8k filing was also a lie….read on.)

Does that January 15, 2020 date ring any bells? It was just a couple of days before huge slugs of stock were granted to insiders. In particular:

and just a week before Cytodyn issued a hypetacular press release filled with absurd claims about loserlimab being beneficial in cancer. Hint: It’s not.

And what does all this have to do with that lawsuit? Paragraph 120 explains it all:

Do we at BuyersStrike! HQ expect anything less from The NaDDir* and his self-dealing Klown Krew? Of course not.

*Spelled thusly for a double dose of that sweet sweet stock pimping.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.